menu

Bispecific Antibodies in FL

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL

Bispecific Antibodies in FL

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. 

    On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b#:~:text=On%20May%2019%2C%202023%2C%20the,or%20more%20lines%20of%20systemic

    On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. To learn more about this approval please visit:  https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Alex Herrera, MD
    Associate Professor, Division of Lymphoma
    Department of Hematology & Hematopoietic Cell Transplantation
    City of Hope
    Duarte, CA

    Nothing to disclose. 

    John P. Leonard, MD
    The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
    Weill Cornell Medicine
    New York, NY

    Nothing to disclose.  

    Kami Maddocks, MD 
    The Ohio State University
    James Cancer Hospital
    Columbus, OH

    Nothing to disclose.  

    Matthew J. Matasar, MD, MS
    Chief, Division of Blood Disorders
    Rutgers Cancer Institute
    Professor, Rutgers Robert Wood Johnson Medical School
    New Brunswick, NJ

    Nothing to disclose.  

    Alison J. Moskowitz, MD
    Associate Attending Physician
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Nothing to disclose.  

    Sarah Rutherford, MD
    Assistant Professor of Medicine
    Division of Hematology/Oncology
    Weill Cornell Medicine
    New York, NY

    Nothing to disclose. 

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo, PSM, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess efficacy and safety outcomes from recent clinical trials in classical Hodgkin lymphoma (cHL)
    • Incorporate recent clinical trial data into practice to optimize treatment selection and survival outcomes for patients with cHL
    • Describe the rationale for newer therapies approved for the treatment of follicular lymphoma (FL)
    • Describe the rationale for newer therapies being evaluated for the treatment of FL
    • Apply recent clinical trial data of bispecific antibodies into treatment planning for patients with FL
    • Apply the safety and efficacy of bispecific antibodies or antibody-drug conjugates being evaluated in patients with DLBCL
    • Assess the safety and efficacy of late-stage bispecific antibodies or antibody-drug conjugates being evaluated in patients with DLBCL
    • Select patients with DLBCL who are eligible for newer therapies
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, hematology oncologists, and pathologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from Genentech, a member of the Roche Group, Genmab, and Seagen Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Jun 2024